Setup. ADMA Biologics makes specialty immune globulin. We flagged it in February at $15.18 as a 14x forward bargain on a yield-enhancement step-change. The Q1 2026 earnings call (May 6) cut guidance, withdrew FY27 outlook, and revealed management constructing a sectoral narrative that two of three largest plasma fractionators publicly rejected within 90 days. Stock fell 44% before we processed the filing.

The call. Revenue guidance was cut from >$635M to $530-560M; adj. NI from >$255M to $170-200M. FY27 long-term guidance was withdrawn — management citing lack of visibility. BIVIGAM (standard polyvalent IG, ≈14% of revenue) collapsed -54% YoY; CEO Adam Grossman: "never wanted to be in standard IG." ASCENIV (specialty hyperimmune for primary immunodeficiency) printed +28% YoY at $97.5M with April single-month utilization the highest ever. Gross margin reached 71% (vs 53% in Q1 2025), reflecting the FDA-approved yield enhancement now fully embedded. Operating cash flow was $58M in Q1 — exceeding all of FY2025's $50M. Cash $138M, leverage <0.5x. Share count down 3.6% on accelerated buyback.

The narrative under cross-corpus test. Grossman framed the BIVIGAM collapse as "first-ever IG market oversupply" with industry growth decelerating from 10-13% to 2-4%. Grifols reported the next day: IG segment +15.3% YoY, CEO directly asked about ADMA's commentary, replied "rational market largely... disciplined own approach." CSL Behring three months prior: "Ig market remains strong... supply balanced," took US Ig price increases. The most likely truth: BIVIGAM lost share to Biotest Yimmugo's US launch (named by Grifols as a successful new entry) and Octapharma/Kedrion SKU additions in the liquid-IG niche. ADMA management reframed competitive failure as industry inflection.

Market versus our view. At current prices, the stock implies ≈10.5x forward on midpoint guidance and ≈$149M FY27 adj. NI (vs withdrawn original >$315M, vs our base estimate ≈$200M). Market is pricing the bear case: continued BIVIGAM decline, ASCENIV deceleration, credibility discount. We agree directionally on BIVIGAM (78% probability of ≥40% FY26 decline) but disagree on magnitude of credibility impairment. RSI 19.6, 10.9% short interest, 14th percentile of 52-week range — technicals deeply oversold and positioning crowded.

Why the gap. Three analysts cover. The narrative contradiction was a small-cap event that received no sell-side synthesis. ASCENIV's structural margin advantage (71% GM, yield enhancement embedded) is real and undercounted at the current multiple. The market priced the cut sympathetically as sector pain, then over-corrected when narrative damage became visible. We see a probability-weighted +13% expected return over 9 months with the Q2 2026 print (~mid-August) as the disambiguation event. Doorway state — neither bull nor bear is yet falsified.

Risks, ranked. (1) Second guidance cut at Q2 validates credibility impairment, breaks long thesis. (2) ASCENIV deceleration below +15% YoY removes the bull foxhole. (3) CFO departure (Item 5.02) — credibility tail event. (4) Multiple compresses further to 8x — value-trap mechanics. (5) Strategic alternatives chatter does not return — removes optionality cushion.

Catalysts. Q2 ADMA print mid-August 2026 (pivotal). GRFS Q2 early-August. TAK FY26 transcript (filed May 13, pending ingestion). PPTA monthly IG data rolling.

What would change our mind. ASCENIV Q2 print ≥$100M with FY26 reaffirmed → modest long shifts to higher conviction. ASCENIV Q2 print <$95M or any second guidance cut → thesis inflects bearish at higher prices. CSLLY's -53.6% YoY collapse (unrelated to IG, currently unexplained) suggests broader plasma-sector idiosyncratic shocks we don't fully understand — investigate before any sector-wide positioning.

Evidence